Association between estimated glomerular filtration rate slope and cardiovascular disease among individuals with and without diabetes: a prospective cohort study

Table 4 Adjusted HRs for study outcomes according to the eGFR and its categories in subjects without diabetes (n=5934)

			Model 1		Model 2		Model 3
	Events/n	Incidence rate per 1000 person-years (95% CI)	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	P trend
The slope of eGFR (mL/min/1.73 m² per year)			1.30 (0.49–3.42)	0.591	1.51 (0.56–4.03)	0.409	1.12 (0.37–3.39)	0.841
Quintiles of Slope of eGFR
Q5 (-0.5198, -0.1679)	167/1186	19.0 (16.3–22.1)	Reference		Reference		Reference		0.786
Q1 (-1.0579, -0.7456)	24/1187	2.5 (1.6–3.7)	0.87 (0.52–1.46)	0.619	0.96 (0.58–1.60)	0.899	1.09 (0.63–1.86)	0.755
Q2 (-0.7454, -0.6711)	36/1187	3.8 (2.7–5.3)	0.91 (0.60–1.39)	0.686	0.98 (0.64–1.48)	0.925	1.06 (0.69–1.63)	0.789
Q3 (-0.6706, -0.6054)	49/1187	5.2 (3.9–6.9)	0.90 (0.62–1.28)	0.569	0.89 (0.62–1.27)	0.527	0.96 (0.66–1.38)	0.826
Q4 (-0.6053, -0.5203)	80/1187	8.5 (6.8–10.6)	1.01 (0.75–1.34)	0.962	0.96 (0.72–1.28)	0.806	0.99 (0.74–1.34)	0.988

Model 1 was adjusted for sex + age
Model 2 was adjusted for model 1 + BMI + smoking status + hypertension + hypercholesterolemia + FH-CVD + marital status + education level + FPG
Model 3 was adjusted for model 2 + eGFR at baseline (index date) + RAAS-I drugs
* The p-value for the trend was computed in Model 3.
HR: hazard ratio; eGFR: estimated glomerular filtration rate; CI: confidence interval; BMI: body mass index; FH-CVD: family history of CVD; FPG: fasting blood glucose; RAAS-I: renin-angiotensin-aldosterone system inhibitors

ISSN: 1475-2840